









Markets
/
Stocks
/
nasdaq-indp
/

Indaptus Therapeutics Inc

INDP

1.800USD

+0.250+16.13%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.96MMarket Cap

LossP/E TTM



Indaptus Therapeutics Inc

1.800

+0.250+16.13%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Indaptus Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Indaptus Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 149 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Indaptus Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

149 / 392

Overall Ranking

294 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Indaptus Therapeutics Inc Highlights

StrengthsRisks

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Overvalued

The company’s latest PE is -0.06, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 106.35K shares, increasing 44.29% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.99.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+545.16%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Indaptus Therapeutics Inc is 7.11, ranking 156 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.11

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Indaptus Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Indaptus Therapeutics Inc is 6.27, ranking 302 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.06, which is -57.30% below the recent high of -0.03 and -3514.45% above the recent low of -2.25.

Score

Industry at a Glance

Previous score

6.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 149/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Indaptus Therapeutics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+458.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Indaptus Therapeutics Inc

INDP

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Indaptus Therapeutics Inc is 6.83, ranking 159 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.13 and the support level at 0.99, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.239

Sell

RSI(14)

36.614

Neutral

STOCH(KDJ)(9,3,3)

13.630

Buy

ATR(14)

0.281

Low Volatility

CCI(14)

-103.762

Sell

Williams %R

84.530

Oversold

TRIX(12,20)

-1.174

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.800

Buy

MA10

2.068

Sell

MA20

2.532

Sell

MA50

2.449

Sell

MA100

2.775

Sell

MA200

6.133

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Indaptus Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.74%, representing a quarter-over-quarter increase of 0.68%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Meckler (Jeffrey A)

229.93K

+1627.10%

Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014

38.26K

Newman (Michael James)

115.55K

+136.45%

Shimoni (Yehuda)

30.90K

Linscott (Walt Addison Esq.)

54.43K

+1088420.00%

Yorkville Advisors Global, LP.

50.39K

Mollick (Thomas)

43.32K

UBS Financial Services, Inc.

102.00

Sassi (Nir)

26.76K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Indaptus Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.